Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
UBS
Express Scripts
Chinese Patent Office
Deloitte
US Department of Justice
Boehringer Ingelheim
Julphar
Federal Trade Commission

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020616

« Back to Dashboard

NDA 020616 describes KADIAN, which is a drug marketed by Allergan Sales Llc and is included in one NDA. It is available from seven suppliers. Additional details are available on the KADIAN profile page.

The generic ingredient in KADIAN is morphine sulfate. There are twenty-three drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
Summary for 020616
Tradename:KADIAN
Applicant:Allergan Sales Llc
Ingredient:morphine sulfate
Patents:0
Therapeutic Class:Analgesics
Formulation / Manufacturing:see details
Pharmacology for NDA: 020616
Mechanism of ActionFull Opioid Agonists
Medical Subject Heading (MeSH) Categories for 020616
Suppliers and Packaging for NDA: 020616
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616 NDA Allergan, Inc. 0023-6011 N 0023-6011-60
KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616 NDA Allergan, Inc. 0023-6012 N 0023-6012-60

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength20MG
Approval Date:Jul 3, 1996TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength50MG
Approval Date:Jul 3, 1996TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength100MG
Approval Date:Jul 3, 1996TE:ABRLD:Yes

Expired US Patents for NDA 020616

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616-002 Jul 3, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616-001 Jul 3, 1996 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616-008 Apr 20, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616-007 Feb 27, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Federal Trade Commission
Cantor Fitzgerald
Dow
Covington
Chinese Patent Office
Cerilliant
Express Scripts
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.